NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Portfolio News / By Karina Tin NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Read More »
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Portfolio News / By Karina Tin Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Read More »
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Portfolio News / By Karina Tin Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Read More »
Circle Pharma presents promising preclinical data on first-in-class oral macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024 Portfolio News / By Karina Tin December 9, 2024 Circle Pharma presents promising preclinical data on first-in-class oral macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024 Read More »
Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting Portfolio News / By Karina Tin December 9, 2024 Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting Read More »
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society Portfolio News / By Karina Tin December 6, 2024 Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society Read More »
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Karina Tin November 25, 2024 Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH) Portfolio News / By Karina Tin November 20, 2024 Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH) Read More »
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer Portfolio News / By Karina Tin November 20, 2024 Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer Read More »
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Portfolio News / By Karina Tin November 15, 2024 Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Read More »
